Francesca DeMartino
No más puestos en curso
Perfil
Francesca M.
DeMartino worked as a Senior Director-Investor Relations at OMRIX Biopharmaceuticals, Inc. from 2006 to 2008.
She then worked as a Director-Investor Relations & Communications at Veloxis Pharmaceuticals A.
In 2014, she was the Head-Investor Relations & Communications at Macrocure Ltd.
From 2015 to 2021, she worked at Medtronic Plc as Vice President-Corporate Communications.
Currently, she is the Senior Vice President-Investor Relations at Becton, Dickinson & Co. and the Chief Investor Relations Officer at BD Multimédia SA. Ms. DeMartino completed her undergraduate degree at the University of California, Berkeley.
Antiguos cargos conocidos de Francesca DeMartino.
| Empresas | Cargo | Fin |
|---|---|---|
| BECTON, DICKINSON AND COMPANY | Investor Relations Contact | 17/10/2023 |
| BD MULTIMEDIA | Investor Relations Contact | 01/10/2023 |
| MEDTRONIC PLC | Public Communications Contact | 01/11/2021 |
| MACROCURE LTD | Investor Relations Contact | 01/08/2015 |
OMRIX Biopharmaceuticals, Inc.
 OMRIX Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OMRIX Biopharmaceuticals, Inc. specializes in the manufacture and development of biosurgical and passive immunotherapy products. Its product range encompasses hemostatic, surgical, and immunotherapy solutions. The firm offers solutions for bleeding control, surgical operations, and biodefense applications. The company was founded by Robert Taub in 1995 and is headquartered in Somerville, NJ. | Public Communications Contact | 01/12/2008 |
Formación de Francesca DeMartino.
| University of California, Berkeley | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| BECTON, DICKINSON AND COMPANY | Health Technology |
| BD MULTIMEDIA | Commercial Services |
| MEDTRONIC PLC | Health Technology |
| Empresas privadas | 3 |
|---|---|
OMRIX Biopharmaceuticals, Inc.
OMRIX Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OMRIX Biopharmaceuticals, Inc. specializes in the manufacture and development of biosurgical and passive immunotherapy products. Its product range encompasses hemostatic, surgical, and immunotherapy solutions. The firm offers solutions for bleeding control, surgical operations, and biodefense applications. The company was founded by Robert Taub in 1995 and is headquartered in Somerville, NJ. | Health Technology |
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
Macrocure Ltd.
 Macrocure Ltd. Medical SpecialtiesHealth Technology Macrocure Ltd. is a clinical-stage biotechnology company, which engages in the development and commercialization of advanced cell therapy products. Its product, CureXcell, is an advanced wound care therapy that treat such wounds by injecting living human white blood cells that have been activate to facilitate the healing process. The company was founded by David Ben-Ami on January 14, 2008 and is headquartered in Petach Tikva, Israel. | Health Technology |
- Bolsa de valores
- Insiders
- Francesca DeMartino
